WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Biden says Brown v. Board of Education ruling was about more than education
Red Stars win at Reign. Angel City tops Courage for its first home win of the year
Lou Groza Award winner Graham Nicholson transferring to Alabama
Foreign trade set to stay resilient this year
Investigators return to Long Island home of Gilgo Beach serial killing suspect
Stone carvings found inside cave of China's Longmen Grottoes
Vibrant festival highlights cultural charm of various Chinese ethnic groups
Damian Lillard sets Bucks' postseason mark with 35 points in opening half vs Pacers
Inquiry slams UK authorities for failures that killed thousands in infected blood scandal
Chinese vice premier stresses speeding up sci
Cruise worker 'murders newborn son on board ship': Shocked co
How Phish is using the Las Vegas Sphere's technology